Abstract: Objective  To investigate the efficacy and safety of tirofiban in acute stage of reocclusion after intravenous thrombolysis in  perforating arterial cerebral infarction.Methods  Totally 21 patients with reocclusion after intravenous thrombolysis in  perforating  arterial cerebral infarction in our department from May 2016 to March 2018 were selected as study group and treated with tirofiban during acute phase. Besides, 32 patients with reocclusion after intravenous thrombolysis  in  perforating  arterial cerebral infarction in our department from January 2011 to April 2016  were collected as control group. There were no significant differences in gender, age, ratio of complicated hypertension and diabetes mellitus, NIHSS score at onset and NIHSS score at reocclusion between the study group and the control group.Results  The improvement of NIHSS score in study group at discharge was significantly better than that in control group(P<0.05). After 3 months of treatment,  the clinical prognosis in study group was significantly better than that in control group(P<0.05). In addition, there were no adverse events such as symptomatic intracranial hemorrhage, hemorrhage in other parts and death in both groups.Conclusion  Early  treatment  of  tirofiban can effectively improve the shortterm clinical symptoms of patients with intravenous thrombolysisin perforating arterial cerebral infarction, which is conducive to improve the longterm clinical prognosis of patients.

Key words: brain Infarction; , perforating , artery, intravenous thrombolysis, tirofiban